RGLS - Regulus Therapeutics Inc Stock Price, Fair Value and News

2.30USD-0.22 (-8.73%)Market Closed

Market Summary

USD2.30-0.22

Market Closed

-8.73%

RGLS Stock Price

View Fullscreen

RGLS RSI Chart

RGLS Valuation

Market Cap

150.6M

Price/Earnings (Trailing)

-5.01

Price/Sales (Trailing)

97.84

EV/EBITDA

-4.34

Price/Free Cashflow

-5.5

RGLS Price/Sales (Trailing)

RGLS Profitability

EBT Margin

-1951.66%

Return on Equity

-141.77%

Return on Assets

-97.68%

Free Cashflow Yield

-18.18%

RGLS Fundamentals

RGLS Revenue

Revenue (TTM)

1.5M

Rev. Growth (Yr)

6.01%

Rev. Growth (Qtr)

-19.41%

RGLS Earnings

Earnings (TTM)

-30.0M

Earnings Growth (Yr)

-18.63%

Earnings Growth (Qtr)

-3.03%

Breaking Down RGLS Revenue

Last 7 days

1.8%

Last 30 days

-20.1%

Last 90 days

81.1%

Trailing 12 Months

76.9%

How does RGLS drawdown profile look like?

RGLS Financial Health

Current Ratio

3.31

RGLS Investor Care

Shares Dilution (1Y)

20.09%

Diluted EPS (TTM)

1.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	989.0K	0	1.4M	1.5M
2022	4.1M	0	2.4M	605.0K
2021	0	10.4M	10.8M	5.9M
2020	7.6M	8.4M	9.2M	10.0M
2019	2.8M	4.1M	5.5M	6.8M
2018	72.0K	72.0K	72.0K	1.4M
2017	913.5K	633.0K	352.5K	72.0K
2016	15.9M	11.0M	6.1M	1.2M
2015	10.2M	13.3M	14.1M	20.8M
2014	18.0M	13.9M	8.9M	7.7M
2013	12.6M	14.0M	17.4M	19.6M
2012	13.8M	13.8M	12.8M	12.7M
2011	9.9M	11.2M	12.5M	13.8M
2010	0	0	0	8.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Regulus Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 14, 2024	papadopoulos stelios	acquired	400,000	1.6	250,000	-
Jan 18, 2024	calsada crispina	sold	-6,510	1.1906	-5,468	chief financial officer
Jan 18, 2024	aker christopher ray	sold	-6,510	1.1906	-5,468	sr. vp & general counsel
Jan 18, 2024	hagan joseph p	sold	-17,358	1.1906	-14,580	chief executive officer
Jan 12, 2024	calsada crispina	acquired	-	-	11,250	chief financial officer
Jan 12, 2024	aker christopher ray	acquired	-	-	11,250	sr. vp & general counsel
Jan 12, 2024	hagan joseph p	acquired	-	-	30,000	chief executive officer
Apr 13, 2023	papadopoulos stelios	acquired	200,000	0.9001	222,198	-
Mar 01, 2022	drygin denis	bought	17,637	0.23	76,686	chief scientific officer
Feb 04, 2022	drygin denis	bought	5,362	0.23	23,314	chief scientific officer

Which funds bought or sold RGLS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	added	2.86	30,000	52,000	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	217,000	217,000	-%
Apr 22, 2024	Vivo Capital, LLC	new	-	14,400,000	14,400,000	1.13%
Apr 17, 2024	GRIMES & COMPANY, INC.	reduced	-1.5	16,222	29,560	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.48	-23,887	366,632	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-36,000	-	-%
Feb 15, 2024	Exome Asset Management LLC	new	-	228,357	228,357	0.23%
Feb 14, 2024	CITADEL ADVISORS LLC	added	142	20,263	36,430	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 14, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	unchanged	-	-3,623	51,533	-%

Are Funds Buying or Selling RGLS?

Are funds buying RGLS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RGLS

No. of Funds

Unveiling Regulus Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	fmr llc	-	0	SC 13G/A
Mar 25, 2024	ra capital management, l.p.	9.5%	6,250,000	SC 13G
Mar 22, 2024	deep track capital, lp	9.99%	6,888,424	SC 13G
Mar 20, 2024	vivo opportunity fund holdings, l.p.	7.7%	5e+06	SC 13G
Mar 18, 2024	growth equity opportunities v, llc	9.99%	6,533,102	SC 13D/A
Feb 14, 2024	dafna capital management llc	5.49%	1,111,049	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 06, 2024	victory capital management inc	5.71%	1,155,516	SC 13G/A
Jan 18, 2024	federated hermes, inc.	19.90%	4,023,860	SC 13G/A
May 12, 2023	growth equity opportunities v, llc	9.99%	1,945,579	SC 13D/A

Recent SEC filings of Regulus Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 30, 2024	DEFA14A	DEFA14A
Apr 19, 2024	EFFECT	EFFECT
Apr 19, 2024	ARS	ARS
Apr 19, 2024	DEF 14A	DEF 14A
Apr 10, 2024	SC 13G/A	Major Ownership Report
Apr 09, 2024	S-3	S-3
Mar 25, 2024	SC 13G	Major Ownership Report
Mar 22, 2024	SC 13G	Major Ownership Report
Mar 21, 2024	10-K	Annual Report
Mar 21, 2024	8-K	Current Report

Peers (Alternatives to Regulus Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.1B	6.8B	3.52%	-17.31%	-8.94	6.15	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-3.68%	-28.69%	-41.18	9.92	76.23%	61.08%
BMRN	15.3B	2.5B	-7.53%	-16.73%	74.64	6.2	13.74%	186.89%
INCY	11.7B	3.8B	-8.64%	-30.91%	15.68	3.1	8.58%	129.81%
MID-CAP
APLS	5.3B	396.6M	-24.84%	-46.72%	-10.08	13.43	425.83%	18.94%
BBIO	4.5B	-	-17.14%	78.66%	-6.9	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.57%	4.22%	-14.61	12.91	440.80%	-27.84%
ARWR	2.8B	240.7M	-20.91%	-36.67%	-9.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-9.63%	-23.17%	-44.93	3.79	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-5.58%	-11.16%	24.84	4.45	85.90%	-14.05%
NVAX	606.0M	983.7M	-9.41%	-43.91%	-1.11	0.62	-50.36%	17.16%
CRBP	388.7M	881.7K	-5.61%	336.79%	-8.71	466.16	-77.61%	-5.33%
INO	267.6M	4.9M	-17.51%	25.55%	-1.98	54.99	-54.97%	51.71%
IBIO	6.0M	2.1M	-57.88%	56.88%	-0.22	2.14	-13.45%	66.37%

Regulus Therapeutics Inc News

Latest updates

Regulus Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Revenue	-19.4%	353,000	438,000	415,000	333,000	187,000	114,000	41,000	1,000	821,000	5,000,000	5,000,000	3,339,333	1,678,667	18,000	18,000	18,000	6,778,000	3,398,000	18,000	18,000	18,000
Operating Expenses	2.2%	8,300,000	8,125,000	7,369,000	6,932,000	7,563,000	6,569,000	6,960,500	8,419,000	6,638,000	6,028,000	6,095,000	6,496,000	5,541,000	4,453,000	5,011,000	4,686,000	9,516,000	8,000,000	9,872,000	13,362,000	15,601,000
S&GA Expenses	-3.8%	2,537,000	2,637,000	2,444,000	2,219,000	2,253,000	2,890,000	2,551,500	2,504,000	2,488,000	2,078,500	2,059,000	2,254,000	2,422,000	2,363,000	2,571,000	2,850,000	3,533,000	2,745,000	2,993,000	3,349,000	3,773,000
R&D Expenses	5.0%	5,763,000	5,488,000	4,925,000	4,713,000	5,310,000	3,679,000	4,409,000	5,915,000	4,150,000	3,950,500	4,036,000	4,242,000	3,119,000	2,090,000	2,440,000	1,836,000	5,983,000	5,255,000	6,879,000	10,013,000	11,828,000
EBITDA Margin	6.6%	-18.98	-20.32	-28.19	-45.47	-11.80	-6.71	-4.52	-1.89	-1.25	-1.34	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-16.8%	114,000	137,000	185,000	196,000	175,000	155,000	213,500	210,000	216,000	392,000	466,000	461,000	489,000	499,000	517,000	538,000	578,000	496,000	620,000	621,000	605,000
Income Taxes	-	-	-	-	-	-	1,000	-	-	1,000	7,000	1,000	-	-8,000	-	-	1,000	-	61,500	-	-	1,000
Earnings Before Taxes	-3.0%	-8,061,000	-7,824,000	-7,139,000	-6,795,000	-7,551,000	-6,718,000	-7,133,000	-8,628,000	-6,033,000	-1,315,000	-1,523,000	-6,947,000	-5,945,000	-4,893,000	-5,423,000	-5,015,000	-3,260,000	-8,502,000	-10,273,000	-13,847,000	-16,024,000
EBT Margin	6.9%	-19.52	-20.95	-29.06	-46.81	-12.16	-6.94	-4.74	-2.03	-1.43	-1.57	-	-	-	-	-	-	-	-	-	-	-
Net Income	-3.0%	-8,061,000	-7,824,000	-7,139,000	-6,795,000	-7,551,000	-6,719,000	-7,133,000	-8,628,000	-6,034,000	-1,322,000	-1,524,000	-6,947,000	-5,937,000	-4,893,000	-5,423,000	-5,016,000	-3,260,000	-8,563,000	-10,273,000	-13,847,000	-16,025,000
Net Income Margin	6.9%	-19.52	-20.95	-29.06	-46.81	-12.16	-6.94	-4.74	-2.03	-1.43	-1.57	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	9.1%	-6,196,000	-6,818,000	-8,115,000	-6,316,000	-6,736,000	-6,483,000	-7,872,000	-5,588,000	-5,155,000	3,189,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-18.5%	31.00	38.00	44.00	37.00	47.00	52.00	54.00	61.00	68.00	43.00	50.00	40.00	38.00	27.00	30.00	35.00	42.00	21.00	26.00	20.00	28.00
Current Assets	-19.7%	28.00	35.00	41.00	35.00	44.00	49.00	51.00	58.00	65.00	40.00	46.00	37.00	37.00	26.00	29.00	34.00	40.00	20.00	24.00	18.00	19.00
Cash Equivalents	-8.0%	24.00	26.00	37.00	30.00	24.00	20.00	35.00	54.00	60.00	36.00	41.00	32.00	31.00	18.00	23.00	28.00	34.00	15.00	20.00	10.00	14.00
Net PPE	5.3%	1.00	1.00	0.00	0.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	8.00
Liabilities	0.8%	10.00	9.00	10.00	10.00	13.00	12.00	12.00	12.00	13.00	14.00	13.00	13.00	12.00	20.00	21.00	20.00	22.00	22.00	21.00	26.00	34.00
Current Liabilities	3.2%	9.00	8.00	8.00	9.00	12.00	11.00	6.00	5.00	5.00	11.00	10.00	10.00	12.00	19.00	21.00	20.00	22.00	21.00	20.00	25.00	27.00
Long Term Debt	-	-	-	-	-	-	-	3.00	4.00	5.00	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	3.00	4.00	5.00	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-25.0%	21.00	28.00	34.00	27.00	33.00	40.00	42.00	49.00	55.00	29.00	37.00	27.00	26.00	8.00	9.00	15.00	20.00	-	5.00	-	-
Retained Earnings	-1.6%	-513	-505	-497	-490	-483	-476	-468	-461	-454	-447	-439	-433	-427	-425	-424	-417	-411	-406	-401	-395	-392
Additional Paid-In Capital	0.2%	534	533	531	517	516	516	511	511	510	477	476	460	453	433	433	432	431	406	406	390	387
Shares Outstanding	0%	20.00	20.00	19.00	17.00	17.00	15.00	15.00	15.00	15.00	8.00	7.00	7.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	27.00	-	-	-	29.00	-	-	-	68.00	-	-	-	23.00	-	-	-	24.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	2.4%	-6,125	-6,277	-6,252	-8,114	-6,253	-6,733	-6,159	-6,381	-7,831	-5,562	-5,024	-5,711	3,189	-4,497	-5,226	-6,002	-4,977	-4,720	-5,691	-4,433	-4,017
Share Based Compensation	6.5%	1,036	973	382	410	397	360	420	1,000	671	807	754	691	470	692	629	823	472	538	319	959	1,067
Cashflow From Investing	190.7%	4,932	-5,440	-	14,999	10,467	-12,861	-12,624	-102	-41.00	-26.00	-131	-53.00	-	-11.00	-	-	-59.00	-141	113	161	6,440
Cashflow From Financing	-404.2%	-873	287	13,207	-805	-	4,489	-	2.00	32,407	-4.00	14,998	6,336	10,055	-1,068	593	-67.00	24,511	-64.00	14,829	657	-2,572

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RGLS Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 21,152	$ 18,410
General and administrative	9,957	9,829
Total operating expenses	31,109	28,239
Loss from operations	(31,109)	(28,239)
Other income (expense):
Interest and other income	1,677	605
Interest and other expense	(604)	(688)
Loss before income taxes	(30,036)	(28,322)
Income tax expense	(1)	(1)
Net loss	(30,037)	(28,323)
Other comprehensive loss:
Unrealized loss on short-term investments, net	0	(12)
Comprehensive loss	$ (30,037)	$ (28,335)
Net loss per share, basic (in dollars per share)	$ 1.58	$ 1.86
Net loss per share, diluted (in dollars per share)	$ 1.58	$ 1.86
Weighted average shares used to compute basic net loss per share (in shares)	18,960,401	15,259,958
Weighted average shares used to compute diluted net loss per share (in shares)	18,960,401	15,259,958

RGLS Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 23,767	$ 24,228
Short-term investments	0	14,932
Restricted cash	62	62
Prepaid materials, net	3,010	3,010
Prepaid expenses and other current assets	1,340	1,847
Total current assets	28,179	44,079
Property and equipment, net	1,061	536
Intangibles, net	33	62
Right of use asset	1,477	2,039
Total assets	30,750	46,716
Current liabilities:
Accounts payable	204	175
Accrued liabilities	691	961
Accrued research and development expenses	921	1,252
Accrued compensation	2,979	2,205
Current portion of term loan, less debt issuance costs	1,334	4,511
Other current liabilities	2,379	2,553
Total current liabilities	8,508	11,657
Operating lease liability, less current portion	1,055	1,768
Total liabilities	9,563	13,425
Commitments and Contingencies
Stockholders’ equity (deficit):
Common stock, $0.001 par value; 300,000,000 shares authorized at December 31, 2023 and 2022; 20,222,672 and 16,840,261 shares issued and outstanding at December 31, 2023 and 2022, respectively	20	17
Additional paid-in capital	534,375	516,457
Accumulated other comprehensive loss	0	(12)
Accumulated deficit	(513,213)	(483,176)
Total stockholders’ equity	21,187	33,291
Total liabilities and stockholders’ equity	30,750	46,716
Class A-1 Convertible Preferred Stock
Stockholders’ equity (deficit):
Convertible preferred stock	0	0
Class A-2 Convertible Preferred Stock
Stockholders’ equity (deficit):
Convertible preferred stock	1	1
Class A-3 Convertible Preferred Stock
Stockholders’ equity (deficit):
Convertible preferred stock	0	0
Class A-4 convertible preferred stock outstanding (as-converted)
Stockholders’ equity (deficit):
Convertible preferred stock	4	4
Class A-5 convertible preferred stock outstanding (as-converted)
Stockholders’ equity (deficit):
Convertible preferred stock	$ 0	$ 0

About Regulus Therapeutics Inc

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

CEO	Mr. Joseph P. Hagan M.B.A.
WEBSITE	regulusrx.com
INDUSTRY	Biotechnology
EMPLOYEES	30

Regulus Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Regulus Therapeutics Inc? What does RGLS stand for in stocks?

RGLS is the stock ticker symbol of Regulus Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Regulus Therapeutics Inc (RGLS)?

As of Tue Apr 30 2024, market cap of Regulus Therapeutics Inc is 150.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RGLS stock?

You can check RGLS's fair value in chart for subscribers.

What is the fair value of RGLS stock?

You can check RGLS's fair value in chart for subscribers. The fair value of Regulus Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Regulus Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RGLS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Regulus Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RGLS is over valued or under valued. Whether Regulus Therapeutics Inc is cheap or expensive depends on the assumptions which impact Regulus Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RGLS.

What is Regulus Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, RGLS's PE ratio (Price to Earnings) is -5.01 and Price to Sales (PS) ratio is 97.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RGLS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Regulus Therapeutics Inc's stock?

In the past 10 years, Regulus Therapeutics Inc has provided -0.444 (multiply by 100 for percentage) rate of return.